Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Vincent

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Journal of Medicinal Chemistry|November 7, 2000
3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinaseA M Thompson, C J Connolly, J M Hamby, et al.
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
Journal of Medicinal Chemistry|February 14, 1997
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congenersH D Showalter, A D Sercel, B M Leja, et al.
Journal of Medicinal Chemistry|May 29, 1999
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.
Journal of Medicinal Chemistry|June 1, 2001
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activityM C Schroeder, J M Hamby, C J Connolly, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Journal of Medicinal Chemistry|August 14, 1998
2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activityS R Klutchko, J M Hamby, D H Boschelli, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumorsJoel T Arcari, Jean S Beebe, Martin A Berliner, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Journal of Medicinal Chemistry|November 7, 2000
3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinaseA M Thompson, C J Connolly, J M Hamby, et al.
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
Journal of Medicinal Chemistry|February 14, 1997
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congenersH D Showalter, A D Sercel, B M Leja, et al.
Journal of Medicinal Chemistry|May 29, 1999
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.
Journal of Medicinal Chemistry|June 1, 2001
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activityM C Schroeder, J M Hamby, C J Connolly, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Journal of Medicinal Chemistry|August 14, 1998
2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activityS R Klutchko, J M Hamby, D H Boschelli, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumorsJoel T Arcari, Jean S Beebe, Martin A Berliner, et al.
Pageof 12